Bank of New York Mellon’s Syndax Pharmaceuticals SNDX Stock Holding History

Bank of New York Mellon’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7M	Buy	1,040,079 +35,581	+4%	+$740K	﹤0.01%	1549
2026 Q1	$23.5M	Sell	1,004,498 -89,653	-8%	-$1.95M	﹤0.01%	1446
2025 Q4	$23M	Buy	1,094,151 +41,816	+4%	+$730K	﹤0.01%	1464
2025 Q3	$16.2M	Buy	1,052,335 +815,234	+344%	+$10.7M	﹤0.01%	1656
2025 Q2	$2.22M	Buy	237,101 +7,343	+3%	+$80.8K	﹤0.01%	2696
2025 Q1	$2.82M	Buy	229,758 +5,497	+2%	+$77.5K	﹤0.01%	2511
2024 Q4	$2.96M	Buy	224,261 +2,759	+1%	+$47.2K	﹤0.01%	2571
2024 Q3	$4.26M	Sell	221,502 -70,324	-24%	-$1.45M	﹤0.01%	2376
2024 Q2	$5.99M	Buy	291,826 +46,463	+19%	+$972K	﹤0.01%	2243
2024 Q1	$5.84M	Buy	245,363 +14,505	+6%	+$323K	﹤0.01%	2245
2023 Q4	$4.99M	Buy	230,858 +3,354	+1%	+$51.6K	﹤0.01%	2375
2023 Q3	$3.3M	Sell	227,504 -7,476	-3%	-$141K	﹤0.01%	2537
2023 Q2	$4.92M	Buy	234,980 +23,257	+11%	+$484K	﹤0.01%	2333
2023 Q1	$4.47M	Buy	211,723 +19,240	+10%	+$479K	﹤0.01%	2364
2022 Q4	$4.9M	Buy	192,483 +3,289	+2%	+$76.7K	﹤0.01%	2352
2022 Q3	$4.55M	Buy	189,194 +22,007	+13%	+$494K	﹤0.01%	2334
2022 Q2	$3.22M	Sell	167,187 -9,204	-5%	-$153K	﹤0.01%	2559
2022 Q1	$3.07M	Buy	176,391 +9,819	+6%	+$165K	﹤0.01%	2694
2021 Q4	$3.65M	Sell	166,572 -1,778	-1%	-$32.9K	﹤0.01%	2630
2021 Q3	$3.22M	Buy	168,350 +21,405	+15%	+$357K	﹤0.01%	2729
2021 Q2	$2.52M	Buy	146,945 +16,430	+13%	+$301K	﹤0.01%	2846
2021 Q1	$2.92M	Hold	130,515	–	–	﹤0.01%	2707
2020 Q4	$2.9M	Buy	130,515 +26,956	+26%	+$559K	﹤0.01%	2630
2020 Q3	$1.53M	Buy	103,559 +18	+0%	+$274	﹤0.01%	2841
2020 Q2	$1.53M	Buy	103,541 +20,919	+25%	+$319K	﹤0.01%	2837
2020 Q1	$906K	Buy	82,622 +7,635	+10%	+$71.7K	﹤0.01%	3054
2019 Q4	$658K	Buy	74,987 +2,642	+4%	+$19.4K	﹤0.01%	3449
2019 Q3	$540K	Buy	72,345 +1,446	+2%	+$13.2K	﹤0.01%	3493
2019 Q2	$659K	Buy	70,899 +4,837	+7%	+$35.3K	﹤0.01%	3462
2019 Q1	$347K	Buy	66,062 +1,026	+2%	+$5.85K	﹤0.01%	3690
2018 Q4	$289K	Buy	65,036 +15,274	+31%	+$83.7K	﹤0.01%	3732
2018 Q3	$402K	Sell	49,762 -30,610	-38%	-$218K	﹤0.01%	3734
2018 Q2	$564K	Buy	80,372 +33,892	+73%	+$333K	﹤0.01%	3580
2018 Q1	$661K	Buy	46,480 +1,304	+3%	+$13.8K	﹤0.01%	3441
2017 Q4	$396K	Sell	45,176 -2,356	-5%	-$23.3K	﹤0.01%	3708
2017 Q3	$556K	Buy	47,532 +3,507	+8%	+$43K	﹤0.01%	3533
2017 Q2	$615K	Buy	44,025 +14,798	+51%	+$169K	﹤0.01%	3505
2017 Q1	$401K	Buy	29,227 +8,861	+44%	+$92K	﹤0.01%	3643
2016 Q4	$146K	Buy	20,366 +3,725	+22%	+$40.8K	﹤0.01%	3961
2016 Q3	$253K	Buy	+16,641	New	+$219K	﹤0.01%	3827

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Bank of New York Mellon's SNDX Position: Q2 2026 in Review

Bank of New York Mellon increased its Syndax Pharmaceuticals (SNDX) stake by 3.5% in Q2 2026, buying an estimated $740K and bringing the position to 1,040,079 shares worth $22.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

Bank of New York Mellon first reported a position in SNDX in Q3 2016 and has held it in 40 quarters since. The position peaked at $23.5M in Q1 2026. 112 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Bank of New York Mellon held 1,040,079 shares of Syndax Pharmaceuticals worth $22.7M as of Q2 2026.
Bank of New York Mellon bought 35,581 Syndax Pharmaceuticals shares in Q2 2026, an estimated $740K.
Syndax Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1549 holding.
Bank of New York Mellon first reported a position in Syndax Pharmaceuticals in Q3 2016 and has held it in 40 quarters since.
Bank of New York Mellon's Syndax Pharmaceuticals position peaked at $23.5M in Q1 2026.
112 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.